U.S. Centers for Disease Control and Prevention • International News

Brazil May Reject Gilead's AIDS Drug Patent

April 11, 2008

On Wednesday, Brazil's Health Ministry decreed Gilead Science's AIDS drug Viread (tenofovir) "in the public interest." The US pharmaceutical firm's patent filing is under review by the country's INPI patent agency, which will consider the ministry's objection in its deliberations.

The ministry said granting the tenofovir patent in Brazil would create "expectations of monopoly rights with an impact on the price of the product."

"If no patent is issued, Brazil will be free to negotiate prices of the drug, be it generic or brand name," a ministry source said Thursday, adding that the issue is "not about compulsory licensing" or patent-breaking.

In Brazil, a Gilead representative declined to comment on the case but said ministry and company officials are in contact about the issue.

The cost of tenofovir represents 10 percent of Brazil's budget for its national AIDS treatment program, which provides free antiretroviral drugs to patients. This year, 31,300 Brazilians will receive tenofovir at a per-patient cost of $1,387 annually, the ministry said. The average treatment cost for each of its 180,000 HIV/AIDS patients is about $2,500 annually.

If Brazil rejects Gilead's tenofovir patent, the country could opt to import a generic version under a World Trade Organization public health exemption.

Back to other news for April 2008

Search the Newsroom archive

Adapted from:
Reuters
04.10.2008; Maria Pia Palermo

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

My Health Tracker

Widgets and RSS Feeds

U.S. ASO Finder

The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV

OIs and Co-Infections and STIs -- Oh, My!

HIV Antiretrovirals in Development: An Update From ICAAC 2009

World AIDS Day 2009: Home

Back From the Brink: A Blog Entry by Thomas DeLorenzo

More >>

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.